- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/40 - Acylated substituent nitrogen atom
Patent holdings for IPC class C07D 213/40
Total number of patents in this class: 572
10-year publication summary
|
45
|
54
|
48
|
33
|
33
|
30
|
31
|
31
|
23
|
11
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Regents of the University of California | 19961 |
10 |
| H. Lundbeck A/S | 1250 |
10 |
| Givaudan SA | 1889 |
9 |
| Genentech, Inc. | 3976 |
8 |
| AstraZeneca AB | 2892 |
8 |
| The General Hospital Corporation | 4740 |
8 |
| The Scripps Research Institute | 1346 |
8 |
| Corteva Agriscience LLC | 2682 |
8 |
| Bristol-myers Squibb Company | 4880 |
7 |
| Amgen Inc. | 4076 |
7 |
| The Broad Institute, Inc. | 1827 |
7 |
| Massachusetts Institute of Technology | 10062 |
6 |
| Abbvie Inc. | 1800 |
6 |
| Curis, Inc. | 132 |
6 |
| Gilead Sciences, Inc. | 2032 |
6 |
| Glenmark Pharmaceuticals S.A. | 120 |
6 |
| Grünenthal GmbH | 565 |
6 |
| Nippon Soda Co., Ltd. | 895 |
6 |
| Ono Pharmaceutical Co., Ltd. | 432 |
6 |
| PTC Therapeutics, Inc. | 485 |
6 |
| Other owners | 428 |